Objective: To identify predictors of clinical disease activity after treatment change to higher-dose interferon beta-1a in relapsing-remitting multiple sclerosis (MS). Methods: This was a retrospective-prospective observational multicenter study. We enrolled patients with at least one relapse on platform injectable therapy who were changed to 44 μg interferon beta-1a. Our primary endpoint was the clinical disease activity-free (cDAF) status at 6, 12, 18, and 24 months. Secondary endponts included relapse-free status and disability progression-free status at different timepoints. The primary predictor of interest was the monosymptomatic vs. polysymptomatic index relapse, based on the number of affected functional systems from the Kurtzke scale during the last relapse prior to baseline. Other secondary predictors of clinical disease activity were analyzed based on different demographic and relapse characteristics. Kaplan-Meier estimates of the cumulative probability of remaining in cDAF status were performed. The time to clinical disease activity was compared between groups using univariate Kaplan-Meier analysis and multivariate Cox regression. Multivariate analyses were processed in the form of CART (Classification & Regression Trees). Results: A total of 300 patients entered the study; 233 (77.7%) of them completed the 24-month study period and 67 patients (22.3%) terminated early. The proportion of patients in cDAF status was 84.7, 69.5, 57.5, and 54.2% at 6, 12, 18, and 24 months. After 2 years of follow-up, 55.9% of patients remained relapse-free and 87.8% of patients remained disability progression-free. At all timepoints, the polysymptomatic index relapse was the most significant predictor of clinical disease activity of all studied variables. Hazard ratio of cDAF status for patients with monosymptomatic vs. polysymptomatic index relapse was 1.94 (95% CI 1.38-2.73). CART analyses also confirmed the polysymptomatic index relapse being the strongest predictor of clinical disease activity, followed by higher number of pre-baseline relapses with the most significant effect in the monosymptomatic index relapse group. The next strongest predictors of clinical disease activity were cerebellar syndrome as the most disabled Kurtzke functional system for the monosymptomatic relapse group, and age at first MS symptom ≥ 45 for the polysymptomatic relapse group. Conclusions: Patients with a polysymptomatic index relapse and/or higher number of relapses within 2 years prior to baseline are at high risk of clinical disease activity, despite treatment change to higher-dose interferon beta-1a from other platform injectable therapy. Trial registration: State Institute of Drug Control (SUKL), URL: http://www.sukl.eu/modules/nps/index.php?h=study&a=detail&id=958&lang=2, registration number 1205090000.

Department of Neurology and Center of Clinical Neuroscience General University Hospital Charles University Prague Czechia

Department of Neurology Krajska zdravotni a s Nemocnice Teplice o z Teplice Czechia

Department of Neurology MS Center Faculty Hospital Palacky University Olomouc Czechia

Merck spol s r o Prague Czechia

Zobrazit více v PubMed

Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. (1993) 43:662–7. 10.1212/WNL.43.4.662 PubMed DOI

The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. (1993) 43:655–61. 10.1212/WNL.43.4.655 PubMed DOI

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. (1995) 45:1268–76. 10.1212/WNL.45.7.1268 PubMed DOI

PRISMS Study Group Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. (1998) 352:1498–504. 10.1016/S0140-6736(98)03334-0 PubMed DOI

PRISMS Study Group University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology. (2001) 56:1628–36. 10.1212/WNL.56.12.1628 PubMed DOI

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, et al. . Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. (2006) 67: 944–53. 10.1212/01.wnl.0000237994.95410.ce PubMed DOI

Kappos L, Freedman MS, Polman CH. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. (2009) 8:987–97. 10.1016/S1474-4422(09)70237-6 PubMed DOI

Kappos L, Kuhle J, Multanen J, Kremenchutzky M, Verdun di Cantogno E, Cornelisse P, et al. . Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry. (2015) 86:1202–7. 10.1136/jnnp-2014-310024 PubMed DOI PMC

Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. . Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology. (2002) 59:1496–506. 10.1212/01.WNL.0000034080.43681.DA PubMed DOI

Panitch H, Goodin D, Francis G, Chang P, Coyle PK, O'Connor P, et al. . Benefits of high-dose, high frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. (2005) 239:67–74 10.1016/j.jns.2005.08.003 PubMed DOI

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. . Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis. Arch Neurol. (2005) 62:785–92. 10.1001/archneur.62.5.785 PubMed DOI

Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. (2007) 29:2031–48. 10.1016/j.clinthera.2007.09.025 PubMed DOI

Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Independent COmparison of INterferon (INCOMIN) trial study group. Lancet. (2002) 359:1453–60. 10.1016/S0140-6736(02)08430-1 PubMed DOI

Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, et al. . Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. (2007) 11:2823–32. 10.1185/03007X233007 PubMed DOI

Karussis D, Biermann L, Bohlega S, Boiko A, Chofflon M, Fazekas F, et al. . A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol. (2006) 13:61–71. 10.1111/j.1468-1331.2006.01147.x PubMed DOI

Masri S, Blodau A, Zessack N, Lang M, for the High Dose High Frequency Study Group Optimizing immunomodulatory therapy with interferon beta in patients with multiple sclerosis a prospective study. Int J MS Care. (2010) 12:147–54. 10.7224/1537-2073-12.4.147 DOI

Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C, et al. . Optimizing immunomodulatory therapy for MS patients: An integrated management model. J Neurol Sci. (2002) 201:89–90. 10.1016/S0022-510X(02)00195-8 PubMed DOI

Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, et al. . Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. (2002) 51:481–90. 10.1002/ana.10148 PubMed DOI

O'Connor P, Kinkel RP, Kremenchutzky M. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Mult Scler. (2009) 15:728–34. 10.1177/1352458509103173 PubMed DOI

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, et al. . Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol. (2008) 255:480–7. 10.1007/s00415-007-0733-2 PubMed DOI

Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B, et al. . The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. (2016) 87:978–87. 10.1212/WNL.0000000000003078 PubMed DOI PMC

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, et al. . Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. (2012) 11:33–41. 10.1016/S1474-4422(11)70262-9 PubMed DOI

Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, et al. . Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol. (2014) 261:490–9. 10.1007/s00415-013-7222-6 PubMed DOI PMC

Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, et al. . Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. (2017) 88:285–94. 10.1136/jnnp-2016-314843 PubMed DOI

Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. (1993) 116:117–34. 10.1093/brain/116.1.117 PubMed DOI

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. (2011) 69:292–302. 10.1002/ana.22366 PubMed DOI PMC

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. (1983) 33:1444–52. 10.1212/WNL.33.11.1444 PubMed DOI

Breiman JH, Olshen L, Friedman RA, Stone CJ. Classification and Regression Trees. Belmont, WA: Wadsworth International Group; (1984).

Marshall RJ. The use of classification and regression trees in clinical epidemiology. J Clin Epidemiol. (2001) 54:603–9. 10.1016/S0895-4356(00)00344-9 PubMed DOI

Lemon SC, Friedmann P, Radowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med. (2003) 26:172–81. 10.1207/S15324796ABM2603_02 PubMed DOI

Friedman JH, Meulman JJ. Multiple additive regression trees with application in epidemiology. Stat Med. (2003) 22:1365–81. 10.1002/sim.1501 PubMed DOI

Gordon L. Using classification and regression trees (CART) in SAS enterprise miner SAS® enterprise miner™ for applications in public health. In: SAS Global Forum 2013 (Paper No. 089–2013). Retrieved from: http://support.sas.com/resources/papers/proceedings13/089-2013.pdf (accessed January 10, 2019).

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. (2017) 376:221–34. 10.1056/NEJMoa1601277 PubMed DOI

Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. . Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. (2015) 373:1418–28. 10.1056/NEJMoa1501481 PubMed DOI

Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. . The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. (1989) 112:1419–28. 10.1093/brain/112.6.1419 PubMed DOI

McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed up until the tenth year or more of the disease. Brain. (1961) 84:186–203. 10.1093/brain/84.2.186 PubMed DOI

Leibowitz U, Alter M. Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand. (1970) 46:53–70. 10.1111/j.1600-0404.1970.tb05604.x PubMed DOI

Kraft GH, Freal JE, Coryell JK, Hanan CL, Chitnis N. Multiple sclerosis: early prognostic guidelines. Arch Phys Med Rehabil. (1981) 62:54–8. PubMed

Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci. (2000) 21:S831–38. 10.1007/s100720070021 PubMed DOI

Wolfson C, Confavreux C. Improvements to a simple markov model of the natural history of multiple sclerosis. Neuroepidemiology. (1987) 6:101–15. 10.1159/000110105 PubMed DOI

Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain. (1990) 113:1597–628. 10.1093/brain/113.6.1597 PubMed DOI

Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. (2001) 189:13–21. 10.1016/S0022-510X(01)00572-X PubMed DOI

Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler. (2006) 12:281–6. 10.1191/135248506ms1278oa PubMed DOI

Coppola G, Lanzillo R, Florio C, Orefice G, Vivo P, Ascione S, et al. . Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol. (2006) 13:1014–21. 10.1111/j.1468-1331.2006.01422.x PubMed DOI

Roullet E, Dominique P, Le Canuet P, Ouallet JC, Giannesini C, Trifan IF, et al. Application of different criteria for clinical response to beta-interferon in relapsing-remitting multiple sclerosis. Neurology. (2003) 60:A168 10.1002/ana.20740 DOI

Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, et al. . Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. (2003) 61:184–9. 10.1212/01.WNL.0000078888.07196.0B PubMed DOI

Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, et al. . Southern ItalyMSGroup. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. (2003) 9:451–7. 10.1191/1352458503ms948oa PubMed DOI

Fromont A, Debouverie M, Le Teuff G, Quantin C, Binquet C, Moreau T. Clinical parameters to predict response to interferon in relapsing multiple sclerosis. Neuroepidemiology. (2008) 31:150–6. 10.1159/000151524 PubMed DOI

Sá MJ, de Sá J, Sousa L. Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey. Neurol Ther. (2014) 3:89–99. 10.1007/s40120-014-0019-4 PubMed DOI PMC

O'Rourke K, Walsh C, Antonelli G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler. (2007) 13:336–42. 10.1177/1352458506071309 PubMed DOI

Goodin D, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, et al. . Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. (2012) 83:282–7. 10.1136/jnnp-2011-301178 PubMed DOI

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. (1996) 46:907–11. 10.1212/WNL.46.4.907 PubMed DOI

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, et al. . Onset of progressive phase is an age dependent clinical milestone in multiple sclerosis. Mult Scler. (2013) 19:188–98. 10.1177/1352458512451510 PubMed DOI PMC

Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. (2007) 255:35–41. 10.1016/j.jns.2007.01.067 PubMed DOI

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. (2011) 77:1246–52. 10.1212/WNL.0b013e318230a17d PubMed DOI PMC

Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. (1980) 103:281–300. 10.1093/brain/103.2.281 PubMed DOI

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. (2006) 129:606–16. 10.1093/brain/awl007 PubMed DOI

Kantarci OH, Siva A, Eraksoy M, Karabudak R, Sütlaş N, Agaoglu J, et al. . Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology. (1998) 51:765–72. 10.1212/WNL.51.3.765 PubMed DOI

Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin. (2005) 23:17–38. 10.1016/j.ncl.2004.10.002 PubMed DOI

Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. . The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. (1989) 112:133–46. 10.1093/brain/112.1.133 PubMed DOI

Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L, et al. . Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology. (1994) 44:28–33. 10.1212/WNL.44.1.28 PubMed DOI

Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler. (2012) 18:45–54. 10.1177/1352458511417479 PubMed DOI

Deen S, Bacchetti P, High A, Waubant E. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry. (2008) 79:1190–3. 10.1136/jnnp.2007.136440 PubMed DOI

Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, et al. . Demyelination versus remyelination in progressive multiple sclerosis. Brain. (2010) 133:2983–98. 10.1093/brain/awq250 PubMed DOI

Confavreux C. Relapses, progression, inflammation and neurodegeneration in multiple sclerosis: a changing view. Adv Clin Neurosci Rehabil. (2002) 2:7–9. 10.1093/brain/awg081 DOI

Held U, Heigenhauser L, Shang C, Kappos L, Polman C, Sylvia, Lawry Centre for MS Research: Predictors of relapse rate in MS clinical trials Neurology. (2005) 65:1769–73. 10.1212/01.wnl.0000187122.71735.1f PubMed DOI

West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology. (2006) 67:809–13. 10.1212/01.wnl.0000234031.30756.a0 PubMed DOI

Tremlett H, Zhao Y, Joseph J, Devonshire V, UBCMS Clinic Neurologists . Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. (2008) 79:1368–74. 10.1136/jnnp.2008.145805 PubMed DOI

Novotna M, Paz Soldán MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, et al. . Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology. (2015) 85:722–9. 10.1212/WNL.0000000000001856 PubMed DOI PMC

Conway BL, Zeydan B, Uygunoglu U, Novotna M, Siva A, Pittock SJ, et al. . Age is a critical determinant in recovery from multiple sclerosis relapses. Mult Scler. (2018) 25:1754–63. 10.1177/1352458518800815 PubMed DOI

Fay AJ, Mowry EM, Strober J, Waubant E. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler. (2012) 18:1008–12. 10.1177/1352458511431725 PubMed DOI

Leone MA, Bonissoni S, Collimedaglia L, Tesser F, Calzoni S, Stecco A, et al. . Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler. (2008) 14:485–93. 10.1177/1352458507084650 PubMed DOI

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. (2003) 61:1528–32. 10.1212/01.WNL.0000096175.39831.21 PubMed DOI

Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. (2009) 72:602–8. 10.1212/01.wnl.0000342458.39625.91 PubMed DOI PMC

Vercellino M, Romagnolo A, Mattioda A, Masera S, Piacentino C, Merola A, et al. . Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand. (2009) 119:126–30. 10.1111/j.1600-0404.2008.01076.x PubMed DOI

Kalincik T. Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology. (2015) 44:199–214. 10.1159/000382130 PubMed DOI

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, et al. . Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. (2017) 23:266–76. 10.1177/1352458516643392 PubMed DOI

Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, et al. MSBase study group . Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler. (2014) 20:1511–22. 10.1177/1352458514528762 PubMed DOI

Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry. (2009) 80:400–3. 10.1136/jnnp.2008.157305 PubMed DOI

Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis. Pathology of recurrent lesions. Brain. (1993) 116:681–93. 10.1093/brain/116.3.681 PubMed DOI

Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, et al. . Assessing changes in relapse rates in multiple sclerosis. Mult Scler. (2010) 16:1414–21. 10.1177/1352458510379246 PubMed DOI

Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric onset compared with adult-onset multiple sclerosis. Arch Neurol. (2009) 66:54–9. 10.1001/archneurol.2008.505 PubMed DOI

Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol. (2009) 256:1061–6. 10.1007/s00415-009-5063-0 PubMed DOI PMC

Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y, UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. (2009) 73:1616–23. 10.1212/WNL.0b013e3181c1e44f PubMed DOI PMC

Goodin DS, Frohman EM, Garmany GP, Jr, Halper J, Likosky WH, Lublin FD, et al. . Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology. (2002) 58:169–78. 10.1212/WNL.58.2.169 PubMed DOI

Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, et al. . Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. (2004) 62:2031–37. 10.1212/01.WNL.0000129265.73259.9E PubMed DOI

Bertolotto A, Deisenhammer F, Gallo P, Sørensen PS. Immunogenicity of interferon beta: differences among products. J Neurol. (2004) 251: II15–24. 10.1007/s00415-004-1204-7 PubMed DOI

Vartanian T, Solberg Sorensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol. (2004) 251:II25–30. 10.1007/s00415-004-1205-6 PubMed DOI